Owkin vs Qure.ai

By valuation, Owkin is the larger company at $1B versus $270M — a 3.7x difference. Size can also be measured by team: Owkin employs 450 people while Qure.ai has 250 employees.

Owkin has raised more in total funding at $334M, compared to Qure.ai's $157M — a gap of $177M. Combined, the two companies have completed 8 known funding rounds.

Qure.ai holds the higher Awaira Score at 70/100, compared to Owkin's 69/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 1-point gap that reflects meaningful differences in scale or traction.

Owkin was founded by Thomas Clozel in 2016. Qure.ai was founded by Prashant Warier in 2016. Visit each company's profile on Awaira for a full founder biography.

Owkin: Owkin is a French AI healthcare company founded in 2016 that develops federated learning and privacy-preserving machine learning technologies for drug discovery and clinical research. The company operates a distributed AI platform enabling pharmaceutical companies, biotech firms, and research institutions to collaborate on data analysis without sharing sensitive patient information or proprietary datasets. Owkin's core technology utilizes federated learning, allowing multiple parties to train machine learning models collectively while maintaining data privacy and regulatory compliance, particularly under GDPR and HIPAA frameworks. The company has raised $334 million in total funding and achieved a $1.0 billion valuation, positioning it as a significant player in the intersection of AI, privacy-tech, and healthcare. Owkin operates in the Series B stage and serves pharmaceutical companies seeking to accelerate drug development through collaborative AI while preserving data confidentiality. The platform addresses a critical challenge in healthcare AI: enabling large-scale machine learning without centralizing sensitive medical data. Owkin's approach contrasts with traditional cloud-based analytics solutions by maintaining data sovereignty at source institutions. The company has established partnerships across the pharmaceutical and research sectors, though specific customer names and financial metrics remain Not disclosed. Its growth trajectory reflects expanding demand for privacy-preserving AI solutions in highly regulated healthcare markets. Owkin combines federated learning with healthcare applications, enabling collaborative AI research without compromising data privacy or regulatory compliance across distributed pharmaceutical ecosystems. Qure.ai: Qure.ai is an Indian artificial intelligence company founded in 2016 that develops machine learning solutions for diagnostic imaging in healthcare. The company specializes in computer-aided detection and diagnosis systems that analyze medical imaging data including chest X-rays, CT scans, and mammograms to identify abnormalities and assist radiologists in clinical decision-making. Its platform uses deep learning algorithms trained on large datasets to detect conditions such as tuberculosis, COVID-19, lung cancer, and other pathologies. Qure.ai's products are deployed across hospitals and diagnostic centers in India and internationally, serving both institutional healthcare providers and diagnostic chains. The company has secured $157 million in total funding and operates at Series D stage with a valuation of $300 million as of recent rounds. Its technology addresses the shortage of radiologists in developing markets while improving diagnostic accuracy and turnaround times. Qure.ai competes in the medical AI space alongside companies like IBM Watson Health, Zebra Medical Vision, and various regional diagnostic AI providers. The company has demonstrated strong traction in the Indian healthcare market and has expanded its reach to international markets. Its growth trajectory reflects increasing adoption of AI-assisted diagnostic solutions globally and the rising demand for scalable healthcare technologies in resource-constrained settings. Qure.ai focuses specifically on diagnostic imaging AI for markets with radiologist shortages, positioning it distinctly within underserved geographies.

Both Owkin and Qure.ai were founded in the same year — 2016. Despite sharing a founding year, they may have launched at different times within that year, which can matter in fast-moving AI markets.

Owkin has approximately 450 employees, while Qure.ai has approximately 250. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Owkin and Qure.ai are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.